Physician profile
Rebecca E Schultz
NPI 1760957351
$4,205.64
in general payments reported to CMS, 2019-2025
29 companies · $711 in 2025
The $711 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $741 · 2022: $939 · 2023: $909 · 2024: $905 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,514 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.50 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $719.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $647.28 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $589.93 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $271.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $223.33 | 2021-2024 | Repatha, Otezla |
| Pfizer INC. | $170.27 | 2021-2025 | |
| Dexcom, INC. | $154.97 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.70 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.64 | 2021-2024 | Jardiance, Ofev |
| Novo Nordisk INC | $122.95 | 2022-2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $115.45 | 2021-2024 | Trintellix |
| Esperion Therapeutics, INC. | $85.57 | 2021-2023 | Nexletol |
| Sunovion Pharmaceuticals INC. | $83.83 | 2021 | |
| Astellas Pharma US INC | $83.76 | 2021-2023 | Veozah |
| Amarin Pharma, INC. | $78.12 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $74.68 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.59 | 2022-2025 | Rexulti |
| Horizon Therapeutics Plc | $74.14 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.03 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $57.82 | 2021-2023 | |
| Lundbeck LLC | $51.59 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $49.18 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.78 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $33.17 | 2021-2022 | |
| Axsome Therapeutics, INC. | $22.61 | 2023 | Auvelity |
| Exact Sciences Corporation | $16.04 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $15.43 | 2023 | Quviviq |
| Globus Medical, INC. | $15.09 | 2025 | Senza |
| Kowa Pharmaceuticals America, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.